Vita Imaging
Vita Imaging is a medical device company developing AURA™, a Raman spectroscopy-based, non-invasive skin cancer detection system that delivers real-time results in under 1.5 seconds for physicians and dermatology practices, currently awaiting FDA Class 3 PMA clearance.
- Company typePrivate
- Founded2019
- HeadquartersFremont, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vita Imaging does
Vita Imaging, Inc. is a privately held medical device company headquartered in Fremont, California, focused on the early detection of pre-cancerous and malignant skin lesions. The company was founded in 2019 and operates with 11–50 employees. Its sole commercial product is AURA™, a non-invasive imaging and spectroscopy system that uses Raman spectroscopy to generate a "molecular fingerprint" of skin lesions and produces real-time diagnostic results in under 1.5 seconds. Clinical studies spanning more than six years and over 800 patients (with more than 1,000 lesions assessed at Vancouver General Hospital) have reported 95% sensitivity with 68.5% specificity and 99% sensitivity with 44.5% specificity for identifying early-stage and malignant skin cancers, including actinic keratosis, basal cell carcinoma, squamous cell carcinoma, and melanoma. A 100-patient US clinical study conducted in Fremont, California between September 2023 and January 2024 supplemented the Vancouver data and was submitted to the FDA on January 17, 2024 as part of a Class 3 Premarket Approval (PMA) application, with a decision expected in the first half of 2025.
The core technology was licensed and co-developed with the British Columbia Cancer Agency (BCCA) and the University of British Columbia (UBC), providing access to a portfolio of eight issued patents in the USA and China covering in vivo Raman endoscopic probes, multimodal Raman/fluorescence spectroscopy, integrated spectral probes, optical calibration standards, ambient-light optical measurement, image-guided micro-Raman spectroscopy, and high-speed Raman spectroscopy apparatus. Key scientific collaborators include Dr. Haishan Zeng, Dr. Harvey Lui, Dr. Sunil Kalia, and Dr. Michael Short. The company is led by Chairman/CEO Thinh Tran (formerly founder and CEO of NASDAQ-listed Sigma Designs and V-Silicon), COO Victoria Reade (with prior FDA 510(k) device approval experience), and Interim CFO Dzung Wright.
Vita Imaging is pre-revenue: AURA™ is not yet available for sale in the US pending FDA clearance. Once approved, the company plans a direct-sales go-to-market targeting dermatologists, primary care physicians, and other healthcare professionals, with revenue generated through hardware device sales to clinical practices. The company has raised approximately $3.36M across five equity crowdfunding rounds on the StartEngine platform between 2020 and February 2026, with no institutional venture capital or private equity investors disclosed in the source data. Its stated longer-term ambition extends beyond skin cancer to "internal organs," leveraging the underlying Raman platform's endoscopic applications.
Vita Imaging firmographics
Firmographics- Name
- Vita Imaging
- Legal name
- Vita Imaging, Inc.
- Website
- https://vita-imaging.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Vita Imaging is a medical device company developing AURA™, a Raman spectroscopy-based, non-invasive skin cancer detection system that delivers real-time results in under 1.5 seconds for physicians and dermatology practices, currently awaiting FDA Class 3 PMA clearance.
- Ownership category
- akta.pro rank
Vita Imaging industry classification
Industry- Product category
- Medical Imaging Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835), Optical Instruments & Lenses (3827)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
Keywords
Where Vita Imaging is headquartered
LocationHeadquarters
- HQ city
- Fremont
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Vita Imaging business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Medical Device Sales: Vita Imaging is developing AURA™ as a medical device for skin cancer detection. Once FDA approval is obtained, the company plans to commercialize the device through direct sales to physicians and healthcare professionals. Revenue will be generated through device sales to clinical practices.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Vita Imaging product offering
Product offeringCore offering
Vita Imaging develops and commercializes AURA™, a Raman spectroscopy-based non-invasive imaging and spectroscopy system that aids physicians in the early detection and diagnosis of pre-malignant and malignant skin cancer lesions. The device generates real-time results in less than 1.5 seconds by identifying spectral changes associated with the biochemistry of skin cancer cells and creating a "molecular fingerprint" for each lesion. AURA™ is currently undergoing FDA Class 3 Premarket Approval review, with data submitted January 17, 2024, and an FDA decision expected in the first half of 2025.
Product overview
Vita Imaging offers a single unified product, AURA™, a Raman spectroscopy-based skin cancer detection system. The company is developing this device as its first commercial product with FDA PMA application currently under review. The technology was jointly developed with British Columbia Cancer Agency (BCCA) and University of British Columbia (UBC), with AURA™ being the first product launched by Vita Imaging targeting skin cancer screening and detection.
Differentiator
Problem solved
Functional benefit
Products and services
- AURA™ AURA™ is a patent-protected, safe, non-invasive imaging and spectroscopy system designed to aid physicians and healthcare professionals in the rapid screening, early detection, and accurate diagnosis of pre-malignant and malignant skin cancer lesions. It generates real-time results in less than 1.5 seconds using Raman spectroscopy to identify spectral changes associated with the biochemistry of skin cancer cells, creating a "molecular fingerprint" for each lesion. The device can rapidly scan 20 to 40 skin lesions on at-risk individuals, supports workflow efficiencies for healthcare providers, and demonstrates 95% sensitivity with 68.5% specificity and 99% sensitivity with 44.5% specificity for malignant skin cancer detection across six years of clinical study on more than 800 patients.
Quantifiable outcome
- 95% sensitivity with 68.5% specificity for skin cancer detection
- +4 more outcomes
Companies that use Vita Imaging
Customer profileSegments2 records
Ideal customer profiles1 record
Vita Imaging technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature3 records
Vita Imaging partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- British Columbia Cancer Agency (BCCA)coreVita Imaging has licensed a revolutionary, patent-protected Raman-based diagnostic platform technology from BCCA. The company partnered with BCCA scientists to develop and refine AURA™ for skin cancer detection. Key scientific collaborators include Dr. Haishan Zeng (Distinguished Scientist & Lead Inventor), Dr. Harvey Lui (Lead Principal Investigator & Co-Inventor), and Dr. Sunil Kalia (Principal Investigator). The technology was developed with extensive testing conducted at Vancouver General Hospital.
- University of British Columbia (UBC)coreVita Imaging partners with UBC researchers for the development of cancer detection technology. Dr. Haishan Zeng serves as Professor of Dermatology, Pathology, and Physics at UBC. Dr. Jianhua Zhao is a Research Associate at both BCCA and UBC. The partnership provides access to world-renowned experts in cancer detection and optical diagnosis.
- Vancouver General HospitalcoreExtensive clinical testing of AURA™ was conducted at Vancouver General Hospital as part of the six-year human clinical study involving over 800 patients and assessment of more than 1,000 lesions.
Scale indicators9 records
Recent moves5 records
Expansion highlights4 records
Vita Imaging competitors and assessment
Company assessmentDirect peers
- DermaSensor: Developer of a non-invasive, FDA Breakthrough-designated point-of-care skin cancer detection device for primary care; the closest direct competitor to AURA in the spectroscopic/AI skin cancer screening category.
- SciBase (Nevisense): Swedish medical device company that markets Nevisense, an electrical impedance spectroscopy-based device for melanoma detection, with FDA cleared indication — the most directly comparable regulatory and commercial profile to Vita Imaging.
- Caliber Imaging & Diagnostics (formerly Lucid): Developer of confocal and reflectance confocal microscopy platforms (VivaScope) for non-invasive skin imaging and diagnosis; competes directly with AURA in the non-invasive skin cancer imaging space.
- Mela Sciences (MelaFind): Historical direct peer that commercialized MelaFind, a multispectral computer-vision skin lesion analysis device for dermatologists; provides a useful regulatory and adoption benchmark for AI/imaging-based skin cancer devices.
Broad incumbents
- FotoFinder Systems: Established German-based provider of digital dermoscopy, total body photography, and AI-assisted skin imaging platforms widely used in dermatology practices; competes with AURA as part of a broader dermatology imaging portfolio.
- Canfield Scientific: Major supplier of dermoscopy, total body photography, and clinical imaging systems used in dermatology and aesthetics; relevant incumbent competing for the same dermatology practice budgets as AURA.
- 3Gen / DermLite: Leading manufacturer of handheld dermatoscopes (DermLite) used in routine skin cancer screening; serves as the established incumbent standard against which AURA's value proposition is judged.
Emerging players
- SkinVision: Amsterdam-based AI smartphone app that assesses skin lesions for cancer risk, with regulatory clearances in Europe; an emerging adjacent player that could triage patients before they reach AURA-equipped specialists.
- MoleSafe: Provider of advanced skin cancer screening and teledermatology services combining total body imaging with specialist review; an emerging service-based competitor in the skin cancer early-detection category.
- MetaOptima Technology (DermEngine): Developer of DermEngine, a teledermatology and AI-dermoscopy platform with mole-tracking and lesion analysis features; an emerging digital-health player with partial overlap in AI-driven skin lesion assessment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Vita Imaging compliance and trust
Trust signalCompliance3 records
Vita Imaging financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vita Imaging leadership team
Management profileNumber of profiles
Profiles3 records
Vita Imaging funding detail
Funding detailFunding overview
Funding rounds5 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vita Imaging M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vita Imaging
What does Vita Imaging do?
Vita Imaging develops and commercializes AURA™, a Raman spectroscopy-based non-invasive imaging and spectroscopy system that aids physicians in the early detection and diagnosis of pre-malignant and malignant skin cancer lesions. The device generates real-time results in less than 1.5 seconds by identifying spectral changes associated with the biochemistry of skin cancer cells and creating a "molecular fingerprint" for each lesion. AURA™ is currently undergoing FDA Class 3 Premarket Approval review, with data submitted January 17, 2024, and an FDA decision expected in the first half of 2025.
Is Vita Imaging a public or private company?
Vita Imaging is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Vita Imaging founded?
Vita Imaging was founded in 2019. It employs 1 to 10 people.
Where is Vita Imaging based?
Vita Imaging is headquartered in Fremont, United States, in the North America region.
How does Vita Imaging make money?
One revenue line is on record: medical Device Sales.
Who are Vita Imaging's main competitors?
Direct peers on record are DermaSensor, SciBase (Nevisense), Caliber Imaging & Diagnostics (formerly Lucid) and Mela Sciences (MelaFind). Broad incumbents are FotoFinder Systems, Canfield Scientific and 3Gen / DermLite. Emerging players are SkinVision, MoleSafe and MetaOptima Technology (DermEngine).
Does Vita Imaging have an API?
No public API is recorded for Vita Imaging.
What industry is Vita Imaging in?
Vita Imaging's product category is Medical Imaging Devices. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI. Its NAICS code is 334510 and its SIC code is 3841.